Recombinant Mouse Frataxin/FXN Protein，His

Frataxin (FXN) is a mitochondrial protein critical for iron-sulfur cluster synthesis and overall mitochondrial function. Its deficiency is primarily associated with Friedreich's ataxia, a genetic disorder characterized by progressive neurological and muscular degeneration. The FXN gene, located on chromosome 9, encodes a 210-amino acid protein that plays a crucial role in cellular iron metabolism and protection against oxidative stress. Research has shown that mutations in the FXN gene lead to reduced frataxin levels, resulting in iron accumulation, mitochondrial dysfunction, and apoptosis in neuronal cells. The need for therapeutic interventions has spurred interest in the recombinant production of frataxin. Recombinant FXN can be utilized to study its biological functions, understand the molecular mechanisms underlying Friedreich's ataxia, and explore potential treatments. Such studies often involve evaluating the effects of frataxin on mitochondrial dynamics, cellular iron homeostasis, and overall cellular health. Additionally, the development of recombinant FXN as a therapeutic candidate could pave the way for innovative treatment strategies, including gene therapy, small molecules that enhance FXN expression, or protein replacement therapies. By deepening our understanding of the role of FXN in the cell and its implications in disease, researchers aim to uncover novel approaches to mitigate the devastating effects of Friedreich's ataxia and improve the quality of life for affected individuals.